Electric with potential

With an in-house R&D unit and academic outreach program in place, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is further entrenching itself in the nascent field of bioelectronics by launching a $50 million strategic fund to invest in young companies developing electroceutical programs.